PetVivo Holdings, Inc. Announces Health Canada Acknowledgement of Spryng® as a Veterinary Medical Device

Core Insights - PetVivo Animal Health, Inc. has received formal acknowledgment from Health Canada for its product Spryng® with OsteoCushion® Technology as a veterinary medical device, marking a significant milestone in the company's global commercialization strategy [1][2][3] Company Overview - PetVivo Holdings, Inc. operates as an emerging biomedical device company focused on innovative medical technologies for companion animals and equine athletes, leveraging human therapies for animal treatment in a capital-efficient manner [6][7] - The company has a robust pipeline of products, including Spryng® and PrecisePRP®, protected by twelve patents and six trade secrets [7] Product Details - Spryng is an intra-articular injectable device designed to support joint health and manage lameness and other joint-related issues in animals [2][4] - The product is currently available in the United States and through select international distribution partners, with plans for commercial availability in Canada anticipated in the second quarter of 2026 [4][3] Regulatory Milestone - The acknowledgment from Health Canada serves as an important endorsement of the company's scientific and regulatory strategy, reflecting its commitment to providing innovative solutions for animal health [3][4] - Despite the regulatory acknowledgment, Spryng is not expected to be immediately available in Canada due to ongoing infrastructure development and operational requirements [3]